About ByHeart
ByHeart is a private company based in New York, New York. It has reported $378,395,005 raised in six offerings on Form D since June 2019. Its chief executive is Ron Belldegrun.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 12, 2025 | Mar 27, 2025amended Mar 31, 2026 | $72,177,578of $173.0M target | 49 | $1.4M | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 28, 2024 | Apr 8, 2024amended May 7, 2026 | $95,493,537of $95.4M target | 46 | $2.0M | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗2 earlier filings |
| Dec 30, 2022 | Jan 13, 2023 | $29,639,049of $60.0M target | 14 | $2.1M | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Jul 9, 2021 | Jul 27, 2021amended Jul 29, 2021 | $62,199,472of $90.0M target | 63 | $987K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Mar 18, 2020 | Apr 1, 2020 | $96,885,369of $102.0M target | 99 | $978K | EquityRule 506(b) | Form D ↗ |
| Jun 11, 2019 | Jun 27, 2019 | $22,000,000fully sold | 49 | $448K | DebtRule 506(b) | Form D ↗ |
| Total, six offerings | $378,395,005 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ByHeart's Form D filed Mar 31, 2026.




Earlier filings also listed Robert Peruzzi (chief financial officer, last listed Jan 2023), Michael Tully (director, last listed Jan 2023), Saloni Varma (executive officer, last listed Jul 2021), James Bauersmith (executive officer, last listed Jul 2021) and Allan Sebbag (executive officer, last listed Apr 2020).
Sources
- SECByHeart, Inc. Form D/A, filed May 13, 2025
- SECByHeart, Inc. Form D, filed Mar 27, 2025
- SECByHeart, Inc. Form D, filed Apr 8, 2024
- SECByHeart, Inc. Form D, filed Jul 27, 2021
- SECByHeart, Inc. filing history
- CompanyTerms and Conditions
- CompanyFDA review update
- CompanyVoluntary recall announcement
- CompanyFinancing announcement
